COS.L Regulatory News (COS)

Collagen Solutions Plc

(the "Company" or the "Group")

Joins consortium developing new treatments for Parkinson's disease

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has been chosen to participate in a new research project to develop novel treatments for Parkinson's disease.

The project is being led by CÚRAM, the Centre for Research in Medical Devices based at NUI Galway, who have secured €4 million in funding through the European Horizon 2020 grant programme. The project, entitled 'Development of Biomaterial-based Delivery Systems for Parkinson's disease - an Integrated Pan-European Approach', facilitates collaboration between world class researchers and industry partners to develop the first disease-modifying therapy for Parkinson's, which could slow down the progression of the disease rather than offering mere symptomatic benefits

As a key member of the consortium, Collagen Solutions will receive significant funding to develop various types of medical grade collagens for investigation over the duration of the project.

Dr Stewart White, CEO of Collagen Solutions plc commented: "Collagen Solutions is delighted to be part of such an esteemed consortium working on developing new therapies for such a devastating condition. I believe our shared success as part of the consortium provides further validation of the Company's reputation for developing and suppling consistent high quality medical grade collagen products for its international clients. Our R&D capabilities, global reach, and state of the art manufacturing facilities in Scotland and New Zealand make us an obvious partner for this exciting project."

Professor Abhay Pandit, Director of CÚRAM, stated that: "CÚRAMs strength lies in establishing unique networks of synergistic national and international collaborations, integrating world class clinical, academic and industrial partners. Collagen Solutions' ability to source, develop and manufacture collagen components for therapeutic use will be critical in meeting the requirements for a functional delivery formulation for the project. It is a mark of quality for all involved to have secured this grant funding, and we are very pleased to welcome Collagen Solutions to the consortium."

Enquiries: